Versigent (NYSE:VGNT) Price Target Cut to $52.00 by Analysts at Royal Bank Of Canada

Versigent (NYSE:VGNT) had its price objective decreased by analysts at Royal Bank Of Canada from $53.00 to $52.00 in a report released on Thursday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Royal Bank Of Canada‘s price objective would suggest a potential upside of 28.17% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the company. The Goldman Sachs Group lowered their price objective on Versigent from $59.00 to $58.00 and set a “buy” rating on the stock in a report on Tuesday, October 6th. Argus raised their target price on Versigent from $50.00 to $54.00 and gave the company a “buy” rating in a research report on Thursday, August 13th. Wells Fargo & Company lifted their price target on Versigent from $48.00 to $56.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 5th. Oppenheimer set a $50.00 price target on Versigent in a research report on Tuesday, July 21st. Finally, Evercore restated an “outperform” rating and issued a $65.00 price objective on shares of Versigent in a report on Monday, August 10th. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $55.00.

Versigent Price Performance

VGNT traded down $1.40 during midday trading on Thursday, hitting $40.57. 586,927 shares of the company traded hands, compared to its average volume of 1,521,932. The company has a current ratio of 1.40, a quick ratio of 1.09 and a debt-to-equity ratio of 7.29. The company has a market capitalization of $2.87 billion and a price-to-earnings ratio of 21.09. Versigent has a 52-week low of $26.34 and a 52-week high of $50.88. The business has a 50 day simple moving average of $45.08 and a two-hundred day simple moving average of $42.71.

Versigent (NYSE:VGNT) last announced its earnings results on Wednesday, November 4th. The company reported $1.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.79 by $0.12. The company had revenue of $2.45 billion during the quarter, compared to analyst estimates of $2.42 billion. On average, equities analysts forecast that Versigent will post 7.23 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Versigent news, Director Kevin Clark sold 47,761 shares of the firm’s stock in a transaction that occurred on Thursday, October 8th. The shares were sold at an average price of $44.36, for a total value of $2,118,677.96. Following the transaction, the director directly owned 27,571 shares of the company’s stock, valued at $1,223,049.56. This trade represents a 63.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last three months, insiders have sold 220,000 shares of company stock valued at $10,065,848.

Institutional Investors Weigh In On Versigent

A number of large investors have recently made changes to their positions in the stock. Fortitude Family Office LLC increased its holdings in shares of Versigent by 497.1% in the third quarter. Fortitude Family Office LLC now owns 621 shares of the company’s stock valued at $28,000 after purchasing an additional 517 shares during the last quarter. Salomon & Ludwin LLC boosted its stake in Versigent by 78.3% during the third quarter. Salomon & Ludwin LLC now owns 708 shares of the company’s stock worth $32,000 after buying an additional 311 shares during the last quarter. Farther Finance Advisors LLC boosted its stake in Versigent by 53.1% during the third quarter. Farther Finance Advisors LLC now owns 1,052 shares of the company’s stock worth $47,000 after buying an additional 365 shares during the last quarter. Signaturefd LLC boosted its stake in Versigent by 40.0% during the third quarter. Signaturefd LLC now owns 1,121 shares of the company’s stock worth $50,000 after buying an additional 320 shares during the last quarter. Finally, Integrated Wealth Concepts LLC purchased a new stake in Versigent in the 2nd quarter valued at $57,000.

Key Stories Impacting Versigent

Here are the key news stories impacting Versigent this week:

• Positive Sentiment: Versigent reported third-quarter sales of $2.45 billion, up 7.2% year over year, and adjusted EPS of $1.91, above the $1.79 consensus estimate. Revenue also topped forecasts of $2.42 billion. Versigent Reports Third Quarter 2026 Results
• Positive Sentiment: The company announced a quarterly dividend of $0.13 per share, equivalent to $0.52 annually and a yield of about 1.2%.
• Neutral Sentiment: BNP Paribas Exane reaffirmed its “outperform” rating and kept a $54 target, implying potential upside from the current share price, but lowered the target from $55. BNP Paribas Exane rating information
• Neutral Sentiment: CFO Doug Ostermann is scheduled to speak at the RBC Capital Markets Global Industrials Conference on November 17. The appearance may provide investors with updates but is not itself a change to the company’s outlook. Versigent CFO conference announcement
• Negative Sentiment: Despite the 7.2% rise in reported sales, adjusted net sales growth was approximately 1% year over year. That more subdued underlying growth may have tempered the market’s response to the earnings beat.

About Versigent

Versigent PLC is involved in the design, manufacturing and delivery of low and high voltage power electrical architectures. Versigent PLC is based in SCHAFFHAUSEN, Switzerland.